
																			10/2
Country Demographics <sup>1,2,3,7</sup>					HBsAg P	Prevale	nce <sup>6</sup>												
Total population (2017) <sup>1</sup> 53,				53,127		Pre-vaccine HBsAG+ (%) 12%													
Urban population (% of total, 2016) <sup>1</sup> 73%				ī	Liver Cancer as Cause of Cancer Death (in Men) <sup>5</sup>														
Health expenditure per capita (\$US, 2016) <sup>2</sup>			016) <sup>2</sup>	\$851.3		Year: 2018					Ranking: NR								
Health expenditure, total (% of GDP, 2016) <sup>2</sup> 2			23.3%	- Th															
Total births (2017) <sup>1</sup> 998						2018 Country Comparison in Western Pacific Region <sup>4</sup>													
Surviving infants (2017) <sup>1</sup>				985			м	Marshall Islands		Highest coverage in WPR			Lowest coverage in WPR						
Life expectancy at birth (years, 2009) <sup>7</sup>					59 yrs		HepB3⁴		84%		100% (Brunei Darussalam, Cook Islands, Niue)			44% (Samoa)					
Number of districts (2013) <sup>3</sup>				3		HepB BD <sup>4</sup>		83%		100% (Cook Islands, Nauru, Palau)			25% (Papua New Guinea)						
Hepatitis B Immunization Coverage <sup>4</sup>																			
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
HepB3 <sup>4</sup>	38%	76%	77%	74%	72%	89%	97%	93%	NR	99%	97%	NR	80%	41%	79%	85%	73%	82%	84%
HepB BD <sup>4</sup>	99%	99%	90%	93%	91%	99%	90%	90%	NR	98%	99%	NR	85%	70%	76%	100%	89%	86%	83%
DTP3 <sup>4</sup>	39%	73%	80%	68%	64%	77%	74%	93%	NR	96%	94%	NR	80%	36%	78%	85%	71%	80%	81%
BCG <sup>4</sup>	89%	89%	90%	93%	91%	93%	92%	92%	NR	98%	99%	NR	97%	93%	89%	100%	94%	92%	98%





Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAg= HepB surface antigen. Data Compiled by APAVH 2019: WHO WPRO Hepatitis B control: country profile 2017<sup>1</sup>, World DataBank: World Development Indicators database<sup>2</sup>, Immunization Summary: A statistical reference containing data through 2013<sup>3</sup>, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary<sup>4</sup>, Global Cancer Observatory: Cancer Today-IARC5<sup>5</sup>, Western Pacific Regional Plan for Hepatitis B control through Immunization<sup>6</sup>, Western Pacific Country Health Information Profiles 2011 Revision<sup>7</sup>, National Immunization Data – EPI summaries by country<sup>8</sup>

Asian Liver Center

National Policies on Hepatitis B Screening for Pregnant Women					
Mandatory HepB screening in all pregnant women (Y/N)					
-If Y, mandatory reporting of HBs-Ag positive pregnant women to public health department (Y/N)					
HBIG administered with HepB BD to infants born to HBsAg positive women (Y/N)					
- If Y, is it free? (Y/N)					

National Policies on Hepatitis B Immunization <sup>8</sup>	
Universal newborn HepB immunization (Y/N) <sup>8</sup>	Y
- If Y, year introduced <sup>8</sup>	1988
-HepB3 nationwide <sup>8</sup>	NR
-Free for all newborns (Y/N)	
-If free, state year introduced:	
Catch-up immunization program for unvaccinated children (Y/N)	
- If Y, year introduced	
-Free for all unvaccinated children (Y/N)	
-If free, state year introduced:	
Immunization program for health care workers (Y/N)	
- If Y, year introduced	
-Free for all health care workers(Y/N)	
-If free, state year introduced:	
HepB newborn immunization included in multiyear plan for EPI (Y/N)	
HepB BD in schedule (Y/N) <sup>8</sup>	Y
Systems to monitor HepB BD <sup>8</sup>	Hospitals, HCs, Homes
Systems to deliver HepB BD <sup>8</sup>	Hospitals, HCs, Homes
HepB vaccine funding other than country government (Y/N)	
-If Y, please specify funding source:	

National Policies on Chronic Hepatitis B Treatm	Certification Status <sup>1</sup>			
Treatment for chronic HBV infection covered (Y/N)		Year certification report received	Pending (2017)	
- If Y, year introduced		Year certification panel convened	NR	
-Interferon (Y/N) -Oral antiviral (Y/N)		Year certification approved	NR	
		Approved with prevalence <1% or <2%?	NR	



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAg= HepB surface antigen. Data Compiled by APAVH 2019: WHO WPRO Hepatitis B control: country profile 2017<sup>1</sup>, World DataBank: World Development Indicators database<sup>2</sup>, Immunization Summary: A statistical reference containing data through 2013<sup>3</sup>, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary<sup>4</sup>, Global Cancer Observatory: Cancer Today-IARC5<sup>5</sup>, Western Pacific Regional Plan for Hepatitis B control through Immunization<sup>6</sup>, Western Pacific Country Health Information Profiles 2011 Revision<sup>7</sup>, National Immunization Data – EPI summaries by country<sup>8</sup>

Asian Liver Center